Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of RBD7022 in participants with normal or elevated LDL-c
NCT05912296Phase 1Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of rbd7022 in hyperlipidemia and hypercholesterolemia (4 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0 at Day 208. Started May 2023; status: completed.
02
Drugs
rbd7022
03
Conditions
hyperlipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT05912296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912296.